| Theme | Development of Diagnosis and Therapy for Biliary Tract Diseases | |
|---|---|---|
| Title | Systemic Chemotherapy for Biliary Tract Cancer | |
| Publish Date | 2010/11 | |
| Author | Tomohiro Yamaguchi | Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital |
| Author | Hideki Ueno | Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital |
| [ Summary ] | Systemic chemotherapy is the mainstay of treatment for patients with unresectable or metastatic biliary tract cancer. However, but no standard chemotherapy modality has been recognized until recently. In 2010, the ABC-02 trial conducted by British investigators showed that gemcitabine with cisplatin exhibited significant survival advantages compared to gemcitabine alone. Gemcitaine plus cisplatin combination therapy is now regarded as the standard regimen for treatment of advanced biliary cancer. Fluoropyrimidines such as 5-FU and S-1, other platinum analogues such as oxaliplatin, and moleculary targeted agents such as cetuximab also have shown potential efficacy for biliary tract cancer treatment. Further randomized trials are required to discover a novel regimen which would be superior to presently used gemcitabine plus cisplatin combination therapies. | |